Cargando…

Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study

INTRODUCTION: Malignant mesothelioma (MM) is an aggressive cancer that primarily arises from the pleura (MPM) or peritoneum (MPeM), mostly due to asbestos exposure. This study reviewed the Dutch population-based incidence, treatment and survival since the national ban on asbestos in 1993. MATERIALS...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Kooten, Job P, Belderbos, Robert A, von der Thüsen, Jan H, Aarts, Mieke J, Verhoef, Cornelis, Burgers, Jacobus A, Baas, Paul, Aalbers, Arend G J, Maat, Alexander P W M, Aerts, Joachim G J V, Cornelissen, Robin, Madsen, Eva V E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Occupational Lung Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685713/ https://www.ncbi.nlm.nih.gov/pubmed/35149582 http://dx.doi.org/10.1136/thoraxjnl-2021-217709

Ejemplares similares

Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program
por: Cantini, Luca, et al.
Publicado: (2020)

Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2021)

Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2020)

Predicting survival in malignant pleural mesothelioma using routine clinical and laboratory characteristics
por: Gunatilake, Samal, et al.
Publicado: (2021)

Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study
por: de Boer, Nadine L., et al.
Publicado: (2019)

Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
por: de Boer, Nadine L, et al.
Publicado: (2019)

Pleural mesothelioma risk in the construction industry: a case–control study in Italy, 2000–2018
por: Stella, Simona, et al.
Publicado: (2023)

Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies
por: Dietz, M.V., et al.
Publicado: (2023)

Metal worker’s lung: spatial association with Mycobacterium avium
por: James, Phillip L, et al.
Publicado: (2018)

Barriers to identifying occupational asthma among primary healthcare professionals: a qualitative study
por: Walters, Gareth I, et al.
Publicado: (2021)

Organophosphate and carbamate insecticide exposure is related to lung function change among smallholder farmers: a prospective study
por: Hansen, Martin Rune Hassan, et al.
Publicado: (2021)

Airborne occupational exposures and the risk of developing respiratory symptoms and airway obstruction in the Lifelines Cohort Study
por: Faruque, Md Omar, et al.
Publicado: (2021)

Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
por: Cornelissen, Robin, et al.
Publicado: (2014)

Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma
por: Minnema-Luiting, Jorien, et al.
Publicado: (2018)

Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study—INTERACT MESO
por: van Kooten, Job P, et al.
Publicado: (2022)

Clustering of malignant pleural mesothelioma in asbestos factories: a subgroup analysis in a 29-year follow-up study to identify high-risk industries in Taiwan
por: Lee, Lukas Jyuhn-Hsiarn, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples – a short report
por: Beije, Nick, et al.
Publicado: (2017)

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
por: Cantini, Luca, et al.
Publicado: (2020)

Communication of a mesothelioma diagnosis: developing recommendations to improve the patient experience
por: Taylor, Bethany Hope, et al.
Publicado: (2019)

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
por: van Haarst, J M W, et al.
Publicado: (2002)

THE CHEESE WHIZ LUNG: HYPERSENSITIVITY PNEUMONITIS IN AN IMITATION CHEESE FACTORY WORKER
por: Bringgold, Will, et al.
Publicado: (2020)

N-95 Face Mask for Prevention of Bird Flu Virus: An Appraisal of Nanostructure and Implication for Infectious Control
por: Wiwanitkit, Viroj
Publicado: (2006)

HYPERBARIC CHAMBER LEADING TO DECOMPRESSION SICKNESS IN PATIENTS WITH COVID-19
por: MUHAMMAD AMIN, SAAD, et al.
Publicado: (2021)

CONTROLLING COVID-19 IN AN ASBESTOS-EXPOSED POPULATION
por: MCNEW, TRACY, et al.
Publicado: (2021)

LOOKING AT THE GROUND GLASS THROUGH COVID-19 COLORED GLASSES: A CASE OF EVALI AMIDST THE COVID-19 PANDEMIC
por: JAGROOP, NIA, et al.
Publicado: (2021)

HYPERSENSITIVITY PNEUMONITIS PRESENTING AS SEVERE CYSTIC LUNG DISEASE FOLLOWING COVID-19 INFECTION
por: YADAV, HARIKA, et al.
Publicado: (2022)

Understanding clinical decision-making in mesothelioma care: a mixed methods study
por: Henshall, Catherine, et al.
Publicado: (2022)

Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score
por: Clive, Amelia O, et al.
Publicado: (2014)

New Roads Open Up for Implementing Immunotherapy in Mesothelioma
por: Cornelissen, R., et al.
Publicado: (2012)

Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial
por: Dietz, Michelle V, et al.
Publicado: (2023)

Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma
por: Sage, Elizabeth K, et al.
Publicado: (2014)

Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy
por: Noordam, Lisanne, et al.
Publicado: (2018)

Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials
por: Mankor, Joanne M., et al.
Publicado: (2020)

In Response to “Intratumor Distribution of Ki-67 Antigen Beyond Labeling Index for Clinical Decision Making: A New Way of Counting”
por: Belderbos, Robert A., et al.
Publicado: (2021)

Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials
por: Wang, Xiaofei, et al.
Publicado: (2017)

Detection of Bacterial Colonization in Lung Transplant Recipients Using an Electronic Nose
por: Wijbenga, Nynke, et al.
Publicado: (2023)

Combination of PD‐1/PD‐L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma
por: van Gulijk, Mandy, et al.
Publicado: (2022)

Staging by Thoracoscopy in potentially radically treatable Lung Cancer associated with Minimal Pleural Effusion (STRATIFY): protocol of a prospective, multicentre, observational study
por: Ferguson, Jenny, et al.
Publicado: (2023)

A study to compare the diagnostic efficacy of closed pleural biopsy with that of the thoracoscopic guided pleural biopsy in patients of pleural effusion
por: Mishra, Ashwini Kumar, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mlqu97o8s2mftdkmto4stv3564